WELCOME: GLOBAL BHP BRAINTRUST
A Message from Andrea Pfeifer, Chair of the Global BHP BrainTrust
Today’s generation will be the last to face untreatable Alzheimer’s disease
In 2022, Leqembi made the headlines as the first disease-modifying treatment to significantly slow the progression of early Alzheimer’s disease. In May, a second immunotherapy (Donanemab) also achieved a positive effect on cognition and function.
Decades of scientific research, clinical trials, and investments have led to these results. Even negative studies contributed to bettering our understanding of the disease and teaching us which elements must be targeted to fight its progression.
In parallel, diagnostic tools, clinical practice, and patient care have also improved and pushed the boundaries to predict who is at risk of developing Alzheimer’s. These breakthroughs pave the way for the next generation of immunotherapies and ultimately, the prevention of Alzheimer’s disease.
While the journey from diagnosis to treatment of dementia remains challenging, impressive efforts on all fronts bring strong reasons for hope. Building the future will require an open dialogue among patients, families, clinicians, and policymakers. We must now advocate for the expansion of clinical infrastructure and reimbursement policies.
Preventing the disease before it causes irreversible damage starts by openly sharing knowledge, the overarching goal of our Global BHP Braintrust.